Clinical Trials on Relapsing-Remitting MS

Total 840 results

Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield; Nottingham Trent University; Sheffield Hospitals Charity

Recruiting

Biomarkers of aHSCT (BIO-MS)

Multiple Sclerosis, Relapsing-Remitting

United Kingdom
Biogen

Recruiting

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

Multiple Sclerosis, Relapsing-Remitting

United States
University Hospital, Basel, Switzerland

Recruiting

MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC

Multiple Sclerosis, Relapsing-Remitting

Switzerland
RemeGen Co., Ltd.

Recruiting

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

Multiple Sclerosis, Relapsing-Remitting

China
Wayne State University

Recruiting

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Active, not recruiting

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Japan
Johns Hopkins University
Genentech, Inc.

Active, not recruiting

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Scripps Health

Withdrawn

Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Providence Health & Services
Microstein, LLC

Completed

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

Multiple Sclerosis, Relapsing-Remitting

United States
Hoffmann-La Roche

Completed

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom, Australia, Belgium, Brazil, Croatia, France, Canada, Slovakia, Germany, Netherlands, Norway, Italy, Poland, Switzerland, Romania, Bulgaria, Spain, Mexico, Austria, Portugal, Turkey, Sweden, Argentina, Denmark and more
Biogen

Terminated

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Multiple Sclerosis, Relapsing-Remitting

Mexico, Turkey, United States, Hungary, Taiwan, Thailand, Korea, Republic of, Saudi Arabia, Malaysia, Colombia, Estonia, Jordan, Tunisia
FibroBiologics

Completed

Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis (MSFibroblast)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Mexico
Charite University, Berlin, Germany

Completed

Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients

Multiple Sclerosis, Relapsing-Remitting

Germany
Mallinckrodt ARD LLC

Terminated

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) (OPTIONS)

Multiple Sclerosis, Relapsing-Remitting

United States
University Hospital Muenster

Unknown

Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis (INCIDENT-MS)

Multiple Sclerosis, Relapsing-Remitting

Germany
GeNeuro SA
Worldwide Clinical Trials; Institut de Recherches Internationales Servier; Les...

Terminated

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis (ANGEL-MS)

Multiple Sclerosis, Relapsing-Remitting

Estonia, Bulgaria, Croatia, Czechia, Germany, Hungary, Italy, Poland, Russian Federation, Serbia, Spain, Ukraine
Rush University Medical Center

Completed

Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Completed

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Belgium, Turkey, Bulgaria, United States, Czechia, Germany, Kuwait, Latvia, Lebanon
University Hospital Muenster
Biogen

Completed

Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Dokuz Eylul University

Completed

Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Turkey
Biogen

Completed

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS (FOCUS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Turkey, United States, Latvia, Lebanon, Germany, Belgium, Bulgaria, Czechia, Kuwait
Transparency Life Sciences

Unknown

Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Completed

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 (StarTec)

Multiple Sclerosis, Relapsing-Remitting

Italy
Genzyme, a Sanofi Company
Bayer

Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two (CARE-MS II)

Multiple Sclerosis, Relapsing-Remitting

Australia, Denmark, Canada, United States, Netherlands, Argentina, Austria, Belgium, Brazil, Croatia, Czech Republic, France, Germany, Israel, Italy, Mexico, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine, United Kingdom
Washington University School of Medicine
Biogen

Withdrawn

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Instituto Jalisciense de Cancerologia
University of Guadalajara; Instituto Mexicano del Seguro Social

Unknown

Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis. (WESTEMDRB1)

Multiple Sclerosis, Relapsing-Remitting

Mexico
GlaxoSmithKline

Completed

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Belgium, Germany, Russian Federation, Spain, Poland
Merck KGaA, Darmstadt, Germany

Completed

A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis (CanTOR)

Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (REMAIN)

Multiple Sclerosis, Relapsing-Remitting
EMD Serono

Completed

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany

Terminated

Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE)

Multiple Sclerosis, Relapsing-Remitting

Denmark
EMD Serono
Merck Serono International SA

Completed

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

Multiple Sclerosis, Relapsing-Remitting
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting
Nelson Mandela Metropolitan University

Unknown

The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis (NIA)

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States, Germany, Austria, Belgium, France, Israel, Italy
Biogen
Elan Pharmaceuticals

Completed

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting
Universität Münster

Recruiting

Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis (CLAProMS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Hasselt University

Recruiting

Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Belgium
Bristol-Myers Squibb

Recruiting

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (SWITCH - ITA)

Multiple Sclerosis, Relapsing-Remitting

Italy
Amsterdam UMC, location VUmc

Recruiting

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis (BLOOMS)

Multiple Sclerosis, Relapsing-Remitting

Netherlands
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-2)

Multiple Sclerosis, Relapsing-Remitting

Turkey, United States, India, United Kingdom, Bosnia and Herzegovina, Estonia, Poland, Romania, Serbia, Ukraine, Armenia, Peru
University of Alabama at Birmingham

Recruiting

Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Berkovich, Regina MD, PhD Inc.
Biogen; Cedars-Sinai Medical Center

Recruiting

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Riley Bove, MD

Recruiting

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (ReWRAP)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Asuman Kucukoner

Completed

Speech in Noise Discrimination Skills in Multiple Sclerosis Patients.

Multiple Sclerosis-Relapsing-Remitting

Turkey
Biogen

Terminated

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Hoffmann-La Roche

Completed

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Canada, United States
Rennes University Hospital

Active, not recruiting

Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis (MS-TRACTS)

Multiple Sclerosis, Relapsing-Remitting

France
Celgene

Completed

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Germany
Biogen

Completed

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Multiple Sclerosis, Relapsing-Remitting

United States, Spain, Canada, Australia, Germany, Italy, United Kingdom, Belgium, Netherlands, France, Israel

Clinical Trials on Relapsing-Remitting MS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations